Speaking back to the divide: Reassembling gender, mobile communication, and AI through feminist data justice in Zambia
Mobile Media & Communication · 28.04.2026
DOI: 10.1177/20501579261443596 ↗Kurz gefasst
Fachartikel in der Zeitschrift Mobile Media & Communication, online erschienen am 28.04.2026. Verfasst von Caroline Wamala Larsson. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Drawing on the Ask Viamo Anything (AVA) Pilot in Zambia, a voice-first generative AI integrated into mobile phones, this article examines how mobile AI platforms reassemble the gendered digital divide. Through a feminist technology studies and feminist data justice lens, it argues that systems like AVA embody both empowerment and constraint: they enable women and youth to engage in private, trusted, voice-based communication while simultaneously reproducing structural exclusions through language, moderation, and infrastructural dependency. This commentary situates mobile AI within mobile communication scholarship, extending its concern with everyday mediation, intimacy, and mobility into the algorithmic age. In doing so, the article illustrates mobile AI as a new communicative form that redistributes agency, visibility, and voice along gendered lines.
Zitieren
APA
Larsson, C. W. (2026). Speaking back to the divide: Reassembling gender, mobile communication, and AI through feminist data justice in Zambia. Mobile Media & Communication. https://doi.org/10.1177/20501579261443596
Vancouver
Larsson CW. Speaking back to the divide: Reassembling gender, mobile communication, and AI through feminist data justice in Zambia. Mobile Media & Communication. 2026. doi:10.1177/20501579261443596
BibTeX
@article{Larsson2026,
author = {Larsson, Caroline Wamala},
title = {Speaking back to the divide: Reassembling gender, mobile communication, and AI through feminist data justice in Zambia},
journal = {Mobile Media & Communication},
year = {2026},
doi = {10.1177/20501579261443596}
}
EUVIMED